BridgeBio to present new acoramidis data on heart failure events at AHA meeting
BBIO•BridgeBio will present ATTRibute-CM analyses of acoramidis and heart failure events at the American Heart Association Scientific Sessions in Chicago on November 6-9, 2026. The November 8 analyses will examine hospitalization risk and recovery after cardiovascular hospitalization.
1. Presentation details
BridgeBio will present new acoramidis data in transthyretin amyloid cardiomyopathy at the American Heart Association Scientific Sessions in Chicago, November 6-9, 2026. ATTRibute-CM analyses scheduled for November 8 will examine heart failure events, hospitalization risk and recovery following cardiovascular hospitalization.
2. Company statement
The company says the data strengthen acoramidis’ clinical profile in transthyretin amyloid cardiomyopathy. Acoramidis is marketed as Attruby in the U.S. and BEYONTTRA in several international markets.
